PacBio to Present at 41st Annual J.P. Morgan Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PacBio (NASDAQ: PACB) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. The company will host a panel discussion on January 10, 2023, at 5:15 PM PT, focused on Multiomics. Additionally, a company presentation and Q&A session will take place on January 11, 2023, at 1:30 PM PT. Live webcasts will be available on PacBio's investors page, with replays accessible for 30 days post-event. PacBio specializes in advanced sequencing solutions aimed at resolving complex genetic problems.
Details
News Market Reaction – PACB
The recorded move for PACB in the trading session of this news was +6.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Dec. 28, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following events at the 41st Annual J.P. Morgan Healthcare Conference:
- Panel | Multiomics: Markers for Modern Medicine on Tuesday, January 10, 2023, at approximately 5:15 PM PT.
- Company presentation and Q&A session on Wednesday, January 11, 2023, at approximately 1:30 PM PT.
The live webcasts of the events can be accessed at the company's investors page at investor.pacificbiosciences.com. Webcast replays will be available for at least 30 days following the presentation.
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB™ short read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
Contacts
Investors:
Todd Friedman
650.521.8450
ir@pacb.com
Media:
Lizelda Lopez
pr@pacb.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/pacbio-to-present-at-41st-annual-jp-morgan-healthcare-conference-301710738.html
SOURCE Pacific Biosciences of California, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.